BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19802009)

  • 1. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
    Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel AKT3 mutation in melanoma tumours and cell lines.
    Davies MA; Stemke-Hale K; Tellez C; Calderone TL; Deng W; Prieto VG; Lazar AJ; Gershenwald JE; Mills GB
    Br J Cancer; 2008 Oct; 99(8):1265-8. PubMed ID: 18813315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new mutational AKTivation in the PI3K pathway.
    Brugge J; Hung MC; Mills GB
    Cancer Cell; 2007 Aug; 12(2):104-7. PubMed ID: 17692802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
    BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thr308 determines Akt1 nuclear localization in insulin-stimulated keratinocytes.
    Goren I; Müller E; Pfeilschifter J; Frank S
    Biochem Biophys Res Commun; 2008 Jul; 372(1):103-7. PubMed ID: 18477468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
    Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
    Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
    Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
    Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
    Tang HJ; Jin X; Wang S; Yang D; Cao Y; Chen J; Gossett DR; Lin J
    Gynecol Oncol; 2006 Feb; 100(2):308-17. PubMed ID: 16209885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
    Kim MS; Jeong EG; Yoo NJ; Lee SH
    Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells.
    Salhia B; Van Cott C; Tegeler T; Polpitiya A; Duquette RA; Gale M; Hostteter G; Petritis K; Carpten J
    Hum Mutat; 2012 Aug; 33(8):1216-27. PubMed ID: 22505016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
    Lauring J; Cosgrove DP; Fontana S; Gustin JP; Konishi H; Abukhdeir AM; Garay JP; Mohseni M; Wang GM; Higgins MJ; Gorkin D; Reis M; Vogelstein B; Polyak K; Cowherd M; Buckhaults PJ; Park BH
    Oncogene; 2010 Apr; 29(16):2337-45. PubMed ID: 20101210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.